Loading...
Homepage 2020-06-12T15:42:29+00:00

HOW WE HELP

0
Donated to NET cancer research
0
Annual visitors to online resources
0
Annual patient email and phone inquiries
0
Patient & caregiver education sessions

NET Cancer is the FASTEST growing class of CANCER worldwide

HELP US HELP OTHERS
HELP US HELP OTHERS

Neuroendocrine Tumours (NETs) Overview

  • Neuroendocrine tumours (NETs) are abnormal growth of cells (neoplasms) that arise from cells of the diffuse neuroendocrine system.
  • NETs are considered complex tumours because both tumor growth and hormonal function must be addressed.
  • NETs are most common in the lung or gastrointestinal system, but they can also originate in other parts of the body such as the thyroid, thymus, pancreas, adrenals, paraganglia, ovaries and testes.
  • NETs are classified as functional (produce hormones that cause symptoms), or non-functional (may or may not produce hormones and do not cause hormonal symptoms).
  • The cause of NETs is currently unknown.
NET ONE PAGE FACTS

CONTACT US

SUPPORT LINES:

416-628-3189

Toll Free: 1-844-628-6788

CNETS NEWS

LUTATHERA® Funded in Ontario

October 10th, 2020|Comments Off on LUTATHERA® Funded in Ontario

Radiopharmaceutical cancer treatment Lutathera® now available to Ontario patients with midgut neuroendocrine tumours (NETs). The Ontario funding criteria covers the treatment of adult patients with somatostatin receptor-positive (SSR+) midgut NETs whose disease has progressed on [...]

LUTATHERA® Funded in Quebec

October 3rd, 2020|Comments Off on LUTATHERA® Funded in Quebec

As of September 30, 2020, the Québec Ministry of Health and Social Services has listed Lutathera on the Liste de Médicaments – Établissements. Lutathera will be reimbursed for GEP-NETs patients with advanced disease that is [...]

LUTATHERA® Funded in Nova Scotia

September 4th, 2020|Comments Off on LUTATHERA® Funded in Nova Scotia

As of August 1, 2020, patients with midgut, GEP-NETs will now be eligible for treatment with LUTATHERA® [lutetium (177Lu) oxodotreotide]. This listing covers adult patients with somatostatin receptor-positive (SSR+) midgut NETs whose disease has progressed [...]

#HoofingIt launches at Peggy’s Cove July 1

July 3rd, 2020|Comments Off on #HoofingIt launches at Peggy’s Cove July 1

HOOFING IT - The summer-long fundraiser launched at Peggy's Cove on July 1st. Sharon Needham, lung neuroendocrine cancer survivor and advocate; family, friends, supporters kicked-off HOOFING IT with a 5km walk along Peggy's Cove [...]

#HoofingIt fundraiser launches at Peggy’s Cove July 1

July 3rd, 2020|Comments Off on #HoofingIt fundraiser launches at Peggy’s Cove July 1

#HoofingIt across Canada to fight one of the fastest-growing class of cancers   Canadian Neuroendocrine Tumour Society (CNETS) launches fundraising challenge at Peggy’s Cove July 1, 2020 HALIFAX­ – Neuroendocrine cancer patients, survivors, [...]

Health Canada Approval of NETSPOT®

April 7th, 2020|Comments Off on Health Canada Approval of NETSPOT®

Advanced Accelerator Applications Announces Health Canada Approval of NETSPOT® Diagnostic Imaging Agent Kit to Detect Neuroendocrine Tumours NETSPOT® is the first and only kit for the preparation of gallium (68Ga) oxodotreotide injection for [...]

Donate to CNETS

CNETS PRIORITIES

SUPPORT

  • In-person peer-led support groups meetings
  • Dedicated patient email and phone support
  • Online private support groups for patients & caregivers

EDUCATION

  • Patient and caregiver education sessions across Canada
  • Robust online patient educational resources
  • Printed educational resources including the NET Reference Guide
  • Annual NET Medical and Scientific Meeting

AWARENESS

  • Raise awareness of NET cancer to the general public & the medical community
  • Participate in World NET Cancer Day Activities

ADVOCACY

  • Assist patients in advocating for access to treatments and diagnostics

RESEARCH

  • Fund Canadian NET cancer research projects